RISPERIDONE TREATMENT OF CHILDREN AND ADOLESCENTS - INCREASED RISK OF EXTRAPYRAMIDAL SIDE-EFFECTS

被引:67
作者
MANDOKI, MW
机构
[1] Division of Child and Adolescent Psychiatry, University of Florida Health Science Center, Jacksonville, FL
关键词
D O I
10.1089/cap.1995.5.49
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
In open clinical trials, 10 children and adolescents (7-17 years) refractory to previous treatments were administered the atypical antipsychotic risperidone (2-6 mg daily). The sample covered a wide range of diagnostic entities, including psychosis, schizophrenia, bipolar disorder, major depression with psychotic features, Tourette's dis order, obsessive-comp ulsi ve disorder, and posttraumatic stress disorder. Risperidone studies in adults have suggested a low incidence of adverse effects, particularly extrapyramidal symptoms. However, 6 of the 10 youths developed extrapyramidal symptoms, and four required the addition of anticholinergic medication. Also, four patients developed dysphoric mood, two of whom met criteria for major depression and required the addition of an antidepressant. Three patients had a significant weight increase. One (age 17) of the 3 adolescent girls developed galactorrhea. Only two patients were free of serious adverse effects. However, all 10 showed overall clinical improvement in their target symptoms during treatment with risperidone. These preliminary and uncontrolled findings do not permit firm; inferences about the safety or efficacy of risperidone. However, the apparently high incidence of adverse effects underscores the risk of generalizing findings in adult studies to children and adolescents, and encourages caution in using newly developed pharmacological agents in the pediatric population. Special care is urged in using risperidone in youth until controlled data are available.
引用
收藏
页码:49 / 67
页数:19
相关论文
共 74 条
[1]  
Akiskal H.S., Dysthymic and cyclothymic depressions: Therapeutic considerations, J Clin Psychiatry, 55, pp. 46-52, (1994)
[2]  
Alvir J.M.J., Lieberman J.A., Safferman A.Z., Schwimmer J.L., Schaaf J.A., Clozapine-induced agranulocytosis, N Engl J Med, 329, pp. 162-167, (1993)
[3]  
American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, (1987)
[4]  
American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, (1994)
[5]  
Amminger G.P., Resch F., Reimitz J., Friedrich M.H., Nebenworkungen von clozapin in der therapie psychotischer zustandbilder bei jungendlichen: Eine retrospektive klinische studie, Z Kinder Jugendpsychiat, 20, pp. 5-11, (1992)
[6]  
Awouters F., Niemegeers C.J.E., Megens A.A.H.P., Janssen P.A.J., Functional interaction between serotonin S-2 and dopamine D-2 neurotransmission as revealed by selective antagonism of hyper-reactivity to tryptamine and apomorphine, J Pharmacol Exp Ther, 254, pp. 945-951, (1990)
[7]  
Barrickman L., Noyes R., Kuperman S., Schumacher E., Verda M., Treatment of ADHD with fluoxetine: A preliminary trial, J Am Acad Child Adolesc Psychiatry, 30, pp. 762-767, (1991)
[8]  
Bersani G., Bressa G.M., MeCo G., Marini S., Pozzi F., Combined serotonin 5-HT2 and dopamine D-2 antagonism in schizophrenia: Clinical, extrapyramidal and neuroendocrine response in a preliminary study with risperidone (R 64 766), Hum Psychopharmacol, 5, pp. 225-231, (1990)
[9]  
Birmaher B., Baker R., Hapur S., Quintana H., Ganguli R., Clozapine for the treatment of adolescents with schizophrenia, J Am Acad Child Psychiatr, 31, pp. 160-164, (1992)
[10]  
Blanz B., Schmidt M.H., Clozapine for schizophrenia [letter], J Am Acad Child Adolesc Psychiatry, 32, pp. 223-224, (1993)